Sapient
Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development.
Latest Sapient Content
Product News
Sapient Extends Multi-Omics Services With High Throughput Discovery Proteomics
New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins.
Product News
Sapient’s High Complexity CLIA Laboratory Receives Accreditation From the College of American Pathologists
Sapient has been awarded accreditation from the College of American Pathologists (CAP).
Industry Insight
Probing the Biomarker Landscape of Human Disease
To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.
Webinar
Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling
On-Demand
Speaking at Proteomics & Metabolomics 2022, Mohit Jain from Bruker, presented their talk on small molecule biomarkers in drug development.
Video
Live from the Lab at Sapient: How timsTOF is helping to transform the speed and scale of small molecule biomarker discovery
Join Bruker's Erica Forsberg with Sapient Founder & CEO Mohit Jain, & Co-Founder and Head of Analytical R&D, Jeramie Watrous as they take you behind the scenes of Sapient’s lab.
Advertisement